RxNews Recap for 08-26-10 Print E-mail
By BioMedReports.com Staff   
Thursday, 26 August 2010 17:05
Below is a list of the companies that made news in the healthcare sector on Thursday, August 26, 2010.

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

CareFusion (NYSE:CFN), a leading, global medical device company, today announced the national commercial launch of the AVAmax® Vertebral Balloon, a minimally invasive device for use during kyphoplasty, a procedure for treating spinal compression fractures.  

Celgene Corporation (NASDAQ: CELG) today announced the appointment of Jacqualyn A. Fouse as Senior Vice President and Chief Financial Officer, effective September 27, 2010.

China-Biotics, Inc. ("China-Biotics," the "Company") (Nasdaq:CHBT), a leading developer, manufacturer and distributor of probiotics products in China, today announced that the Company is ranked 62nd on FORTUNE's 2010 "Fastest-Growing Companies" list.

China Pediatric Pharmaceuticals, Inc. (OTC Bulletin Board: CPDU) ("China Pediatric Pharmaceuticals" or the "Company"), today announced its financial results for the second quarter ended June 30, 2010.

Cypress Bioscience, Inc. (NASDAQ: CYPB), a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system (CNS) disorders, today announced that it has acquired patent rights and technology related to a novel, intranasal formulation of carbetocin, a potential breakthrough treatment for the core symptoms of autism.

Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it received CE Mark approval to market its expanded offering of Powerlink® stent graft products and PowerFit™ Aortic Extensions in the European Union.

Lotus Pharmaceuticals, Inc. (OTC Bulletin Board:LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC"), announced today that it has entered R-Bambuterol(R) Clinical Trial I on-schedule and is on-track to complete in six months.

Luminex Corporation (Nasdaq:LMNX), the worldwide leader in multiplexed solutions, today announced the full commercial launch of its xTAG® Cystic Fibrosis 60 Kit v2, a new diagnostic test that can simultaneously screen a single blood sample for up to 60 cystic fibrosis-causing genetic mutations in a matter of hours.  

MMRGlobal, Inc. (OTCBB: MMRF) (http://www.mmrglobal.com) is a sponsor of The Gulf is Back, a one-hour TV special on the CW Network airing this Friday, August 27, 2010, at 8:00 p.m. ET.

NMT Medical, Inc. (NASDAQ: NMTI) today announced that, effective immediately, Richard E. Davis has been named chairman, president and chief executive officer.Mr. Davis previously served as NMT's chief operating officer.

Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today target market details for the domestic and international commercialization of its Onko-Sure® in vitro diagnostic (IVD) cancer test.

Shire plc (LSE: SHP, NASDAQ:SHPGY), the global specialty biopharmaceutical company, announced today that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease.

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that abstracts of three studies involving its PD2i® nonlinear algorithm have been accepted for presentation during the Poster Session of the 2010 Heart-Brain Summit.

XenoPort, Inc. (Nasdaq:XNPT) announced today that William J. Rieflin has been elected to the XenoPort Board of Directors, effective September 17, 2010, and he will resign as president of XenoPort to accept a position as chief executive officer of a private biotech company.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus